Last reviewed · How we verify
Combined Oral Contraceptive Pill
At a glance
| Generic name | Combined Oral Contraceptive Pill |
|---|---|
| Also known as | Portia |
| Sponsor | Columbia University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Anxiety and Depression in Adolescent PCOS (NA)
- A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants (PHASE1)
- A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause (PHASE1)
- The Influence of Combined Oral Contraception on the DEvelopment and progRession of Chronic venoUs diSeases (NA)
- A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (PHASE1)
- Relative Desirability of Metformin vs. Birth Control Pill in Treating PCOS in Women of Later Reproductive Age (EARLY_PHASE1)
- Oral Contraceptive Pills Versus Levonorgestrel-Releasing Intrauterine System for Niche-Related Abnormal Uterine Bleeding (NA)
- The Effect Of Polycystic Ovarian Syndrome Treatment On Ocular Surface.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combined Oral Contraceptive Pill CI brief — competitive landscape report
- Combined Oral Contraceptive Pill updates RSS · CI watch RSS
- Columbia University portfolio CI